CardioExchange Archive

September 7th, 2012

News Briefs: Cholesterol Trends, AHA Late-Breakers, FDA Updates On Rivaroxaban And Heartware HVAD

Larry Husten, PHD

Cholesterol Trends The Centers for Disease Control issued a new report with the latest details about the prevalence of cholesterol screening and high blood cholesterol in U.S. adults. Here is their summary of the key findings: …cholesterol screening increased from 72.7% in 2005 to 76.0% in 2009, whereas the percentage of those screened who reported being told […]

---

August 13th, 2012

Selections from Richard Lehman’s Literature Review: August 13th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include using existing data for new research; normal weight, diabetes, and non-CVD death; cholesterol levels in U.S. kids; statins and diabetes; HDL-C and MI protection; statin treatment; hypertension treatment; clopidogrel and PPIs; and an analysis behind the “innovation crisis” of the pharmaceutical industry.

---

August 7th, 2012

Survey Finds Significant Drop in Cholesterol Levels in Youths

Larry Husten, PHD

New data from the National Health and Nutrition Examination Survey (NHANES), published in JAMA, show significant and perhaps surprising  improvements over the last 20 years in the lipid profile of youths aged 6-19 years. Among the key lipid parameters measured by the survey from 1988-1994 to 2007-2010: Total cholesterol decreased from 165 mg/dL to 160 mg/dL (p<0.001) Prevalence of […]

---

May 17th, 2012

Study Casts Doubt on Protective Effects of Raising HDL Cholesterol

Physician's First Watch, CardioExchange Staff

A genetics-based analysis finds that raising HDL will not necessarily lower risk for myocardial infarction. Reporting in the Lancet, researchers describe a two-pronged approach. First, they searched for the presence of a specific allele (LIPG Asn396Ser, associated with higher HDL levels in carriers) in a large cohort of subjects with and without MI. The allele’s presence […]

---

August 10th, 2011

Rethinking Trilipix — And the Process for Approving Lipid-Modifying Drugs

Sanjay Kaul, MD

Editor’s Note: In an article published in the New England Journal of Medicine, three members of the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (Allison Goldfine, Sanjay Kaul, and William Hiatt) offer their perspective on the May 19 committee meeting to review the controversial ACCORD-Lipid Study. Here, one of those authors, Sanjay Kaul, provides his […]

---

February 17th, 2011

Quarter of U.S. Adults 45 and Older Taking Statins

Larry Husten, PHD

One-quarter of U.S. adults age 45 and older are taking statins, and one-half of men ages 65 to 74 are taking these drugs, according to the CDC’s annual report on trends in health statistics. From 1988 to 1994, only 2% of adults age 45 and older were taking statins. High cholesterol levels have been declining, according to […]

---

February 3rd, 2011

Lancet Papers Outline Worldwide Trends in Obesity, Hypertension, and Cholesterol

Larry Husten, PHD

Three papers published in the Lancet provide the most detailed view yet of worldwide trends over the last 3 decades in body-mass index (BMI), blood pressure, and cholesterol, and also include numerous details about different regions and countries. Here are a few highlights of the reports from the Global Burden of Metabolic Risk Factors of Chronic […]

---

November 23rd, 2010

How Should We DEFINE Anacetrapib’s Success?

Philip John Barter, MD, PhD and Christopher Paul Cannon, MD

CardioExchange welcomes Philip Barter and Christopher P. Cannon, two of the investigators for the DEFINE trial, which was recently published in the New England Journal of Medicine. Here, they answer questions posed by CardioExchange’s editors. First, some background about the trial: In DEFINE, 1623 patients with or at high risk for coronary disease were randomized to receive […]

---

November 19th, 2010

Will This Be the HDL Decade? REVEAL Revealed, Mixed Results for Apo-A1

Larry Husten, PHD

For a long time, HDL has been called the “good cholesterol.” Are we now entering the HDL decade? Two HDL-related trials were presented Wednesday at the AHA, and an array of additional trials are planned or underway, prompting the lead investigator of one of those trials, Chris Cannon, to speculate that this decade may be […]

---

November 10th, 2010

Alzheimer’s Disease and Cholesterol: A Tricky Relationship

Larry Husten, PHD

A recent study in Neurology found that cholesterol levels in mid-life were not linked to the development of Alzheimer’s disease in older age. In fact, the study by Michelle Mielke and colleagues found that large drops in cholesterol levels in old age were a harbinger of Alzheimer’s. CardioExchange asked Cynthia Carlsson, Assistant Professor and Alzheimer’s researcher […]

---